• By Concept
  • By Last Name
  • By Full Text

Mufson, Elliott J

Grant Detail

The grant detail shows the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the fingerprint of the grant. If any publications referencing this grant are found in the data, they will be listed here as well.



Epidemiology of Dementia In An Urban Community

Mayeux, Richard

1 February 1989 - 30 June 2009
NATIONAL INSTITUTE ON AGING
Total Funding: $ 40,531,208

FY 2008
5P01AG007232-20
$ 2,276,976
FY 2007
5P01AG007232-19
$ 2,308,243
FY 2006
5P01AG007232-18
$ 2,355,854
FY 2005
5P01AG007232-17
$ 2,589,384
FY 2004
2P01AG007232-16
$ 2,313,454
FY 2003
5P01AG007232-15
$ 2,405,115
FY 2002
5P01AG007232-14
$ 2,374,020
FY 2001
5P01AG007232-13
$ 2,479,208
FY 2000
5P01AG007232-12
$ 2,524,865
FY 2000
3P01AG007232-11A1S1
$ 73,949
FY 1999
2P01AG007232-11A1
$ 1,933,919
FY 1999
3P01AG007232-10S1
$ 265,366
FY 1998
5P01AG007232-10
$ 1,929,852
FY 1997
5P01AG007232-09
$ 1,679,805
FY 1997
3P01AG007232-09S2
$ 37,687
FY 1997
3P01AG007232-09S1
$ 294,206
FY 1996
5P01AG007232-08
$ 1,696,521
FY 1995
5P01AG007232-07
$ 1,728,163
FY 1994
2P01AG007232-06
$ 1,359,287
FY 1994
3P01AG007232-06S1
$ 45,448
FY 1993
5P01AG007232-05
$ 1,833,000
FY 1992
5P01AG007232-04
$ 1,509,729
FY 1992
3P01AG007232-04S1
$ 341,730
FY 1991
5P01AG007232-03
$ 1,447,037
FY 1990
5P01AG007232-02
$ 1,427,432
FY 1989
1P01AG007232-01A1
$ 1,300,958
 
 
$ 40,531,208
Abstract

Since its inception in 1989, the Washington Heights and Inwood and Columbia Aging Project (WHICAP) has investigated rates and risk factors of Alzheimer's disease (AD) and related dementias in a multi-ethnic, urban community. In the previous five-year funding cycle, we made several key observations that have helped us to frame this new proposal. We found that elevated levels of plasma Abeta42 were associated with incident AD, that memory performance in elderly without dementia declines over time in those who with an ApoE4 allele compared with other APOE genotypes and that memory performance can be directly related to decreased basal metabolism in the hippocampus measured by magnetic resonance imaging (MRI). We established the first estimates of the prevalence and incidence rates of mild cognitive impairment (MCI) among elderly African-Americans and Caribbean Hispanics, comparing these estimates to the frequency of MCI in Caucasians. We found that rates of AD were higher among individuals following stroke and those with high insulin levels. We also observed found that mortality was increased by five-fold for individuals with newly diagnosed AD and that factors such as home health care extended survival and delayed nursing home admissions. In the previous cycle we also successfully recruited 2,103 individuals age 65 years and older, supplementing the survivors of the original cohort established in 1992. This new cohort, termed WHICAP II includes 2,767 individuals for which biological samples and clinical data are available from the baseline assessment. A Clinical Assessment Core, Epidemiology-Data Management-Statistical Core, Neuropathology and Molecular core are continued, and a Brain Imaging Core has been added to support five new projects. In addition to Alzheimer's disease (AD), this study will also examine mild cognitive impairment (MCI) as an outcome. In four of the five projects, we will include magnetic resonance imaging of brain. Each of the projects represents a direct extension from the work done in the previous 3 funding cycles. In Project 1 we will investigate plasma Abeta42 and both structural and function MRI as antecedent biomarkers in relation to the risk of MCI, AD and cognitive decline. In project 2, we will examine hyperinsulinemia, related cardiovascular and stroke as risk factors for MCI, AD and cognitive decline. Project 3 will continue to examine factors related to the progression of AD and its consequences. In Project 4, will examine parkinsonism as a risk factor for MCI and AD and examine imaging of basal ganglia. Project 5, will examine olfactory dysfunction as an antecedent risk factor for MCI and AD. The overall theme of this fourth renewal application is to identify reliable and valid antecedent biomarkers of AD and MCI and to extend these and other clinical parameters to the measurement of disease progression.

294 Resulting Publications

Scientific Context

This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.

Related Grants

Related Publications